MarquisA (ponazuril) Antiprotozoal Oral Paste, marketed in North America for over a decade, treats equine protozoal myeloencephalitis (EPM) a disease that affects the central nervous system in horses.
What does EPM stand for?
EPM stands for Equine Protozoal Myeloencephalitis
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of EPM
We have 230 other meanings of EPM in our Acronym Attic
- Enterprise Portal Management
- Enterprise Process Management
- Enterprise Procurement Manager
- Enterprise Project Management
- Enterprise Project Manager
- Entreprise Plomberie Manzanares (French plumbing company)
- Entreprise Provençale de Menuiserie (French carpentry company)
- Environmental Planning and Management
- Epilepsy with Progressive Myoclonus (neurology)
- Equal-Probability Measurement
- Equipment Performance Measurement
- Equivalent Parts per Million
- Eritrean People's Movement (Eritrea)
- Escola Portuguesa de Macau (Macao, China)
- ESD (Earth Surface Dynamics) Program Management
- Espace Plaine Montagne (French: Plain Mountain Area)
- Espace Plongée Martinique (French diving club)
- Espace Public Multimédia (French: Public Area Multimedia)
- Estes Park Medical (Estes Park, CO)
- Estes Park Museum (Colorado)
Samples in periodicals archive:
Food and Drug Administration (FDA) to market and sell NAVIGATOR(R) (32% nitazoxanide) Antiprotozoal Oral Paste, a new treatment for equine protozoal myeloencephalitis (EPM), a progressive, degenerative disease of the central nervous system that can cause serious or even fatal neurological problems in horses.
Sarcocystis neurona is a parasite responsible for Equine Protozoal Myeloencephalitis (EPM).
EBI's proprietary technology is a highly specific diagnostic test for equine protozoal myeloencephalitis (EPM), an emerging neurologic disease which causes economic loss to the horse industry.
IDEXX Pharmaceuticals also has a number of products in the registration process with the FDA, including a nitazoxanide-based product for treatment of equine protozoal myeloencephalitis -- a neurological disease that is believed to affect approximately 200,000 horses in the US; a topical non-steroidal anti-inflammatory for equine use; an insulin product for the treatment of diabetic cats; and a long-acting injectable antibiotic for cats are also in development.
Food and Drug Administration has informally told the Company that it is likely to issue an incomplete letter regarding the Company's new animal drug application (NADA) for nitazoxanide, a drug intended for the treatment of equine protozoal myeloencephalitis.
The Company is seeking FDA approval of a number of other drugs for companion animals, including a treatment for equine protozoal myeloencephalitis (EPM), a non-steroidal anti-inflammatory, and a novel, long-acting antibiotic for companion animals.
The new company is a leading-edge veterinary biotechnology company whose first product is the world's only reliable test for equine protozoal myeloencephalitis (EMP), which causes severe damage to horses' central nervous systems.